High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q4
100.75M
+2.56%
-0.137
+95.54%
113.80M
-2.01%
-0.043
-316.65%
Estimates Revision
The market is revising Downward the revenue expectations for Ardelyx, Inc. (ARDX) for FY2025, with the revenue forecasts being adjusted by -2.4% over the past three months. During the same period, the stock price has changed by 29.87%.
Revenue Estimates for FY2025
Revise Downward
-2.4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+0.38%
In Past 3 Month
Stock Price
Go Up
+29.87%
In Past 3 Month
10 Analyst Rating
0Wall Street analysts forecast ARDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARDX is 11.22 USD with a low forecast of 8.00 USD and a high forecast of 15.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
0Current: 5.130
Low
8.00
Averages
11.22
High
15.00
0Current: 5.130
Low
8.00
Averages
11.22
High
15.00
Jefferies
Buy
maintain
$8
2025-07-02
Reason
Jefferies
Price Target
$8
2025-07-02
maintain
Buy
Reason
Jefferies reiterated a Buy rating and $8 price target on Ardelyx. The firm noted that the stock is trading 5%-10% higher Wednesday morning on a sizable volume, and that it's unclear why. A potential reason could be from an update on the Xphozah CMS appeal, which Jefferies has been flagging as a significant call option not in buyside expectations, the analyst tells investors in a research note. The firm added that a new docket update this week set a date for oral arguments in September 25, and that a positive appeals decision by the end of the year could restore Part D for Xphozah and add a large growth driver for the stock.
H.C. Wainwright
H.C. Wainwright
initiated
$10
2025-06-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$10
2025-06-19
initiated
Reason
H.C. Wainwright assumed coverage of Ardelyx with a Buy rating and $10 price target. The company has demonstrated approval and commercial execution with Ibsrela for the treatment of irritable bowel syndrome with constipation in adults and Xphozah for treating hyperphosphatemia, the analyst tells investors in a research note. The firm sees near-term commercial progress for Ardelyx.
Scotiabank
Louise Chen
Buy
Initiates
$15
2025-03-07
Reason
Scotiabank
Louise Chen
Price Target
$15
2025-03-07
Initiates
Buy
Reason
Ladenburg Thalmann
Aydin Huseynov
Strong Buy
Initiates
$11
2025-03-07
Reason
Ladenburg Thalmann
Aydin Huseynov
Price Target
$11
2025-03-07
Initiates
Strong Buy
Reason
Ladenburg lowered the firm's price target on Ardelyx to $11 from $13.50 and keeps a Buy rating on the shares following a transfer of analyst coverage.
HC Wainwright & Co.
Ed Arce
Hold
Reiterates
$5.5
2025-02-21
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$5.5
2025-02-21
Reiterates
Hold
Reason
Raymond James
Ryan Deschner
Strong Buy
Reiterates
$15 → $13
2025-02-21
Reason
Raymond James
Ryan Deschner
Price Target
$15 → $13
2025-02-21
Reiterates
Strong Buy
Reason
Raymond James lowered the firm's price target on Ardelyx to $13 from $15 and keeps a Strong Buy rating on the shares. Management reaffirmed Q4 net sales figures that were pre-announced, including $158.3M in Ibsrela and $160.9M in Xphozah 2024 net product sales, and management reiterated their commitment to driving strong commercial execution with the newly expanded field team, the analyst tells investors in a research note. Continued enthusiasm that Xphozah weekly scripts are still in a range suggesting a continued growth trajectory was offset by guidance outlining meaningful 2025 SG&A spend increases that weighed on shares on Thursday, the firm says.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ardelyx Inc (ARDX.O) is -15.39, compared to its 5-year average forward P/E of -11.35. For a more detailed relative valuation and DCF analysis to assess Ardelyx Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.35
Current PE
-15.39
Overvalued PE
-1.72
Undervalued PE
-20.99
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-14.36
Current EV/EBITDA
154.84
Overvalued EV/EBITDA
28.09
Undervalued EV/EBITDA
-56.80
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
29.92
Current PS
2.75
Overvalued PS
85.08
Undervalued PS
-25.23
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 129.11% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
ARDX News & Events
Events Timeline
(ET)
2025-08-04
17:36:15
Ardelyx CFOO Justin Renz to depart, John Bishop named CTOO
2025-06-02 (ET)
2025-06-02
16:09:02
Ardelyx appoints Mike Kelliher Chief Business Officer
2025-05-06 (ET)
2025-05-06
08:24:10
Ardelyx presents data supporting IBSRELA at DDW 2025
Sign Up For More Events
Sign Up For More Events
News
Preview
2.0
08-05NASDAQ.COMArdelyx (ARDX) Shares Cross Above 200 DMA
Preview
3.0
08-02SeekingAlphaArdelyx Q2 2025 Earnings Preview
Preview
7.0
07-02SeekingAlphaArdelyx spike attributed to Xphozah legal update
Sign Up For More News
People Also Watch
FAQ
What is Ardelyx Inc (ARDX) stock price today?
What is Ardelyx Inc (ARDX)'s business?
What is the price predicton of ARDX Stock?
What is Ardelyx Inc (ARDX)'s revenue for the last quarter?
What is Ardelyx Inc (ARDX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ardelyx Inc (ARDX)'s fundamentals?
How many employees does Ardelyx Inc (ARDX). have?